Evidence map›Paper›PMID 36267843›Full record

ArticleBioMed research international2022

Long Noncoding RNA DSCAM-AS1 Facilitates Proliferation and Migration of Hemangioma Endothelial Cells by Targeting miR-411-5p/TPD52 Axis.

Yulong Wang, Shuiting Zhai, Jianwu Xing, Jinchi Zhang, Yingkun He, Guoquan Wang, Tianxiao Li

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Non-coding RNA in infantile hemangioma.Pediatric research · 2024
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yulong WangThe Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471000 Henan, China.
Shuiting ZhaiDepartment of Vascular Surgery, The People's Hospital of Henan Province, Zhengzhou City, 450000 Henan Province, China.
Jianwu XingThe Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471000 Henan, China.
Jinchi ZhangThe First Affiliated Hospital of Fujian Medical University, Fuzhou, 350000 Fujian, China.
Yingkun HeZhengzhou University People's Hospital, Henan Provincial People's Hospital and Henan Provincial Neurointerventional Engineering Research Center, Zhengzhou City, 450000 Henan Province, China.
Guoquan WangDepartment of Vascular Surgery, The People's Hospital of Henan Province, Zhengzhou City, 450000 Henan Province, China.
Tianxiao LiZhengzhou University People's Hospital, Henan Provincial People's Hospital and Henan Provincial Neurointerventional Engineering Research Center, Zhengzhou City, 450000 Henan Province, China.ORCID https://orcid.org/0000-0002-6686-6048
Henan Provincial People's Hospital · CNHenan University of Science and Technology · CNZhengzhou University · CNFujian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diagnosed as a kind of vascular neoplasm of infancy, hemangioma (HA) occurs mainly due to the aberrant proliferation of endothelial cells. Existing evidence has manifested the close relationship of long noncoding RNAs (lncRNAs) with the pathogenesis of HA. Although lncRNA DSCAM antisense RNA 1 (DSCAM-AS1) has been revealed to be implicated in the progression of human diseases, the underlying mechanism DSCAM-AS1 exerts in HA formation is unclear. Aims: To figure out how DSCAM-AS1 may regulate the progression of human hemangioma endothelial cells (HemECs). Methods: DSCAM-AS1 expression was verified through RT-qPCR detection. Functional assays including EdU assay, colony formation assay, flow cytometry analysis, TUNEL assay, and transwell assay were applied to evaluate cell proliferation, apoptosis, and migration upon DSCAM-AS1 knockdown. Moreover, RNA pull-down assay, luciferase reporter assay, RIP assay, and other mechanism experiments were utilized for evaluating the correlation of DSCAM-AS1 and RNAs in HemECs. Results: DSCAM-AS1 knockdown inhibited proliferative capability and migratory capability of HemECs whereas expedited apoptosis. Molecular mechanism results testified DSCAM-AS1 could function as a ceRNA to bind miR-411-5p in HemECs. Besides, it was confirmed that tumor protein D52 (TPD52) served as a downstream target of miR-411-5p in HemECs. More importantly, related rescue assays uncovered that elevated expression of TPD52 or inhibited expression of miR-411-5p reversed the repressive progression of HemECs mediated by DSCAM-AS1 depletion. Conclusion: DSCAM-AS1 expedited HA progression via miR-411-5p/TPD52 pathway, which provided a novel therapeutic option for HA treatment.

Indexed as

HemangiomaMicroRNAsRNA, Long NoncodingCell Line, TumorCell ProliferationEndothelial CellsGene Expression Regulation, NeoplasticHumansNeoplasm ProteinsTranscription FactorsMicroRNAsMIRN411 microRNA, humanNeoplasm ProteinsRNA, Long NoncodingTPD52 protein, humanTranscription Factors

Identifiers

PMID36267843
PMCPMC9578823
OpenAlexW4304589275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.